CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
CDKI AT7519 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00390117
NCT00390117Phase 1Completed
CompareCT.gov

A Phase I Study of AT7519M Given Twice Weekly in Patients With Advanced Incurable Malignancy

NCIC Clinical Trials Group·interventional·Posted Oct 19, 2006·Updated Aug 4, 2023

In Brief

A Phase 1 clinical trial evaluating CDKI AT7519 and laboratory biomarker analysis for Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 34 participants across 2 sites.

Detailed Summary

RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced or metastatic solid tumors or refractory non-Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Unspecified Adult Solid Tumor, Protocol Specific
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 2006
Enrollment StartJan 5, 2007
Primary CompletionMar 13, 2012
Study CompletionJan 10, 2013
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 19.7 years ago

Interventions

CDKI AT7519drug

AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.

laboratory biomarker analysisother

Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.